Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial

Study limitation reported by the research below: “Efficacy endpoints (e.g., HbA1c change, weight loss) are not reported in this abstract; the primary endpoint was safety only.”